HILDEN, Germany & TOKYO--(BUSINESS WIRE)--Aug 1, 2018--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration with SRL, Inc., the largest clinical testing laboratory company in Japan, to prepare for introduction of new companion diagnostics simultaneous with new drug approvals. The non-exclusive master collaboration agreement for clinical laboratory research services will enable rapid implementation by SRL of QIAGEN´s companion diagnostic workflows upon approval of the drugs and tests by Japan’s Pharmaceutical and Medical Devices Agency (PMDA). Several tests QIAGEN is co-developing with pharmaceutical partners are expected to enter registration in Japan in the coming years.

QIAGEN’s Day-One Lab Readiness initiative with SRL includes strategic planning for market access to companion diagnostics, filing for reimbursement, and alignment of medical communication by SRL, QIAGEN and pharmaceutical partners. The agreement will cover a range of QIAGEN companion diagnostics, including real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS) solutions for Personalized Healthcare. Initial projects involve QIAGEN companion diagnostics paired with new drugs under development in Japan for solid tumors and leukemia.

Please find the full press release here

View source version on businesswire.com:https://www.businesswire.com/news/home/20180801005098/en/

CONTACT: QIAGEN

Investor Relations

John Gilardi, +49 2103 29 11711

Dr. Sarah Fakih, +49 2103 29 11457

e-mail:ir@QIAGEN.com

or

Public Relations

Dr. Thomas Theuringer, +49 2103 29 11826

Robert Reitze, +49 2103 29 11676

e-mail:pr@QIAGEN.com

or

SRL

Investor Relations / Public Relations

Hidefumi Nagasaka, +81 3 5909 3337

e-mail:mhd.pr@miraca.com

KEYWORD: UNITED STATES EUROPE ASIA PACIFIC NORTH AMERICA GERMANY NEW YORK JAPAN

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: QIAGEN N.V.

Copyright Business Wire 2018.

PUB: 08/01/2018 03:30 AM/DISC: 08/01/2018 03:30 AM

http://www.businesswire.com/news/home/20180801005098/en